|
26
|
150
|
4g6mA |
Crystal structure of human il-1beta in complex with therapeutic antibody binding fragment of gevokizumab |
|
27
|
152
|
4gafA |
Crystal structure of ebi-005, a chimera of human il-1beta and il-1ra, bound to human interleukin-1 receptor type 1 |
|
27
|
149
|
4g6jA |
Crystal structure of human il-1beta in complex with the therapeutic antibody binding fragment of canakinumab |
|
41
|
142
|
4g9mA |
Crystal structure of the rhizoctonia solani agglutinin |
|
30
|
152
|
4gaiA |
Crystal structure of ebi-005, a chimera of human il-1beta and il-1ra |
|
40
|
142
|
4g9nA |
Crystal structure of the rhizoctonia solani agglutinin in complex with n'-acetyl-galactosamine |
|
96
|
421
|
4fvvA |
Crystal structure of hcr/d-sa-gbl1/c |
|
31
|
114
|
4g1rA |
Crystal structure of anti-hiv actinohivin in complex with alphs-1,2-mannobiose (form ii) |
|
99
|
428
|
3r4uA |
Cell entry of botulinum neurotoxin type c is dependent upon interaction with two ganglioside molecules |
|
94
|
428
|
3r4sA |
Cell entry of botulinum neurotoxin type c is dependent upon interaction with two ganglioside molecules |
|
31
|
124
|
4fgfA |
Refinement of the structure of human basic fibroblast growth factor at 1.6 angstroms resolution and analysis of presumed heparin binding sites by selenate substitution |
|
33
|
177
|
3qydA |
Crystal structure of a recombinant chimeric trypsin inhibitor |
|
30
|
171
|
3qr5A |
Structure of the first domain of a cardiac ryanodine receptor mutant with exon 3 deleted |
|
32
|
124
|
3q7yA |
Crystal structure of k15r/e18d/y22w/h41g/f44w/e51d/e53p/k57r/e60d/y64w/h82g/f85w/e90d/e94p/k98r/e101d/y108w/h129g/f132w/e137d symfoil-4p: de novo designed beta-trefoil architecture with symmetric primary structure |
|
35
|
124
|
3q7wA |
Crystal structure of symfoil-4p/pv1: de novo designed beta-trefoil architecture with symmetric primary structure, primitive version 1 |
|
76
|
235
|
3pubA |
Crystal structure of the bombyx mori low molecular weight lipoprotein 7 (bmlp7) |
|
32
|
125
|
3q7xA |
Crystal structure of symfoil-4p/pv1: de novo designed beta-trefoil architecture with symmetric primary structure, primitive version 1 |
|
79
|
285
|
3phzA |
Crystal structure analysis of polyporus squamosus lectin bound to human-type influenza-binding epitope neu5aca2-6galb1-4glcnac |
|
110
|
417
|
3pmeA |
Crystal structure of the receptor binding domain of botulinum neurotoxin c/d mosaic serotype |
|
132
|
486
|
3p53A |
Structure of fascin |
|
32
|
166
|
3pokA |
Interleukin-1-beta lbt l3 mutant |
|
34
|
125
|
3p6jA |
Crystal structure of symfoil-4t permutation #3: de novo designed beta-trefoil architecture with symmetric primary structure |
|
51
|
140
|
3pg0A |
Crystal structure of designed 3-fold symmetric protein, threefoil |
|
33
|
135
|
3oj2A |
Crystal structure of fgf1 complexed with the ectodomain of fgfr2b harboring the a172f pfeiffer syndrome mutation |
|
33
|
133
|
3ojvA |
Crystal structure of fgf1 complexed with the ectodomain of fgfr1c exhibiting an ordered ligand specificity-determining betac'-betae loop |
|
108
|
414
|
3oggA |
Crystal structure of the receptor binding domain of botulinum neurotoxin d |
|
37
|
145
|
3ojmA |
Crystal structure of fgf1 complexed with the ectodomain of fgfr2b harboring p253r apert mutation |
|
14
|
81
|
3ogfA |
Crystal structure of difoil-4p homo-trimer: de novo designed dimeric trefoil-fold sub-domain which forms homo-trimer assembly |
|
36
|
127
|
3p6iA |
Crystal structure of symfoil-4t permutation #2: de novo designed beta-trefoil architecture with symmetric primary structure |
|
36
|
123
|
3o4dA |
Crystal structure of symfoil-4p: de novo designed beta-trefoil architecture with symmetric primary structure |
|
140
|
581
|
3o44A |
Crystal structure of the vibrio cholerae cytolysin (hlya) heptameric pore |
|
37
|
123
|
3o4bA |
Crystal structure of symfoil-4t: de novo designed beta-trefoil architecture with symmetric primary structure |
|
34
|
123
|
3o4aA |
Crystal structure of symfoil-2: de novo designed beta-trefoil architecture with symmetric primary structure |
|
31
|
123
|
3o3qA |
Crystal structure of "l44f/m67i/l73v/a103g/deletion 104-106/f108y/v109l/l111i/c117v/r119g/deletion 120-122" mutant form of human acidic fibroblast growth factor |
|
34
|
123
|
3o49A |
Crystal structure of symfoil-1: de novo designed beta-trefoil architecture with symmetric primary structure |
|
112
|
420
|
3obrA |
Crystal structure of botulinum neurotoxin serotype d binding domain |
|
34
|
124
|
3o4cA |
Crystal structure of symfoil-4v: de novo designed beta-trefoil architecture with symmetric primary structure |
|
22
|
152
|
3o4oA |
Crystal structure of an interleukin-1 receptor complex |
|
104
|
420
|
3obtA |
Crystal structure of botulinum neurotoxin serotype d ligand binding domain in complex with n-acetylneuraminic acid |
|
76
|
262
|
3o5wB |
Binding of kinetin in the active site of mistletoe lectin i |
|
30
|
159
|
3nj5A |
Crystal structure of chicken il-1 hydrophobic cavity mutant 157 |
|
91
|
424
|
3n7kA |
Crystal structure of botulinum neurotoxin serotype c1 binding domain |
|
94
|
415
|
3n7jA |
Crystal structure of botulinum neurotoxin serotype d binding domain |
|
41
|
148
|
3nbcA |
Clitocybe nebularis ricin b-like lectin (cnl) in complex with lactose, crystallized at ph 4.4 |
|
42
|
147
|
3nbeA |
Clitocybe nebularis ricin b-like lectin (cnl) in complex with n,n'-diacetyllactosediamine |
|
94
|
422
|
3n7mA |
Crystal structure of w1252a mutant of hcr d/c vpi 5995 |
|
43
|
148
|
3nbdA |
Clitocybe nebularis ricin b-like lectin (cnl) in complex with lactose, crystallized at ph 7.1 |
|
96
|
422
|
3n7lA |
Crystal structure of botulinum neurotoxin serotype d/c vpi 5993 binding domain |
|
33
|
150
|
3n0kA |
Proteinase inhibitor from coprinopsis cinerea |
|
103
|
433
|
3mppG |
Botulinum neurotoxin type g receptor binding domain |
